



Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026

October 7, 2026

WILMINGTON, Del., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, November 4, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter.

Third Quarter 2026 Conference Webcast Details:

- **What:** Clover Health's Third Quarter 2026 Earnings Conference Call
- **When:** Wednesday, November 4, 2026, at 5:00 p.m. Eastern Time
- **Webcast:** To access the webcast, you may register at <https://clover-health-3q-2026-earnings.open-exchange.net/>.

A live and archived webcast of the conference call will also be accessible from the Investor Relations section of Clover Health's website at <https://investors.cloverhealth.com/> for 12 months.

About Clover Health:

Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on [Medication Adherence](#), [Congestive Heart Failure](#), [Chronic Obstructive Pulmonary Disease](#), and in [Underserved Populations](#) as well as the earlier identification and management of [Diabetes](#) and [Chronic Kidney Disease](#).

Investor Relations:

Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:

press@cloverhealth.com